Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

ISRCTN	ISRCTN71212234
DOI	https://doi.org/10.1186/ISRCTN71212234
Secondary identifying numbers	H14

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details below to request a patient information sheet
Scientific title	Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Lymphoma (Hodgkin's)
Intervention	Patients are randomised to one of two chemotherapy regimens: 1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses. 2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Not Applicable
Drug / device / biological / vaccine name(s)
Primary outcome measure	Not provided at time of registration
Secondary outcome measures	Not provided at time of registration
Overall study start date	01/01/1989
Completion date	01/10/1993

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Target number of participants	Not provided at time of registration
Key inclusion criteria	1. Hodgkin's lymphoma stage IIB, III or IV 2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV) 3. Local hisopathological review of diagnosis 4. No medical contraindications to treatment protocols
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1989
Date of final enrolment	01/10/1993

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

21/01/2019: No publications found. All search options exhausted.